"Treatment Of Amyotrophic Lateral Sclerosis" in Patent Application Approval Process (USPTO 20230054101).
In: Gene Therapy Weekly, 2023-03-17, S. 3497-3497
serialPeriodical
Zugriff:
The present invention therefore provides NMD agents for use in medicine, and specifically in treatment or prevention (e.g., delay of onset) of certain neurological disorders including specifically amyotrophic lateral sclerosis (ALS). There is no effective treatment for the disease; the only approved ALS drug (riluzole) extends the lifespan of some ALS patients by only about 3 months. Keywords: Amyotrophic Lateral Sclerosis; Biotechnology; Cells; Central Nervous System Diseases and Conditions; Drugs and Therapies; Genetics; Health and Medicine; Motor Neuron Disease; Neurodegenerative Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Neurons; Patent Application; Spinal Cord Diseases and Conditions; TDP-43 Proteinopathies; Therapeutics; Therapy EN Amyotrophic Lateral Sclerosis Biotechnology Cells Central Nervous System Diseases and Conditions Drugs and Therapies Genetics Health and Medicine Motor Neuron Disease Neurodegenerative Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Neurons Patent Application Spinal Cord Diseases and Conditions TDP-43 Proteinopathies Therapeutics Therapy 3497 3497 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent application by the inventors Ju, Shulin (Beavercreek, OH, US); Petsko, Greg (New York, NY, US); Ringe, Dagmar (Cambridge, MA, US), filed on April 15, 2022, was made available online on February 23, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Treatment Of Amyotrophic Lateral Sclerosis" in Patent Application Approval Process (USPTO 20230054101).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2023-03-17, S. 3497-3497 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|